Alpha 2.0
Login Register
» Authors » George Siber

George Siber

Explore the profile of George Siber including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 460
Followers 0
Related Specialties
Allergy & Immunology
Infectious Diseases
General Medicine
Top 10 Co-Authors
Donna Ambrosino
Ralf Clemens
Branda Hu
Igor Smolenov
Htay Htay Han
David Goldblatt
Joshua Liang
Richard Malley
Robert Kohberger
Ronald Smulders
Published In
Vaccine
J Infect Dis
Lancet
Lancet Infect Dis
Hum Vaccin Immunother
Affiliations
Soon will be listed here.
Recent Articles
1.
Corrigendum to "Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years" [Vaccine 40 (2022) 4190-4198]
Chichili G, Smulders R, Santos V, Cywin B, Kovanda L, Van Sant C, et al.
Vaccine . 2024 Jun; 42(23):126023. PMID: 38897894
No abstract available.
2.
Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial
Borys D, Rupp R, Smulders R, Chichili G, Kovanda L, Santos V, et al.
Vaccine . 2024 Feb; 42(10):2560-2571. PMID: 38360475
Background: Pneumococcal conjugate vaccines (PCVs) significantly reduced pneumococcal disease burden. Nevertheless, alternative approaches for controlling more serotypes are needed. Here, the safety, tolerability, and immunogenicity of a 24-valent (1/2/3/4/5/6A/6B/7F/8/9N/9V/10A/11A/12F/14/15B/17F/18C/19A/19F/20B/22F/23F/33F) pneumococcal...
3.
SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
Roa Jr C, de Los Reyes M, Plennevaux E, Smolenov I, Hu B, Gao F, et al.
Hum Vaccin Immunother . 2024 Jan; 20(1):2301632. PMID: 38206168
We assessed the non-inferiority of homologous boosting compared with heterologous boosting with the recombinant protein vaccine, SCB-2019, in adults previously immunized with different COVID-19 vaccines. Three equal cohorts (N ~ ...
4.
Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults
Roa Jr C, de Los Reyes M, Plennevaux E, Smolenov I, Hu B, Gao F, et al.
J Infect Dis . 2023 Jul; 228(9):1253-1262. PMID: 37439701
Background: We compared homologous and heterologous boosting in adults in the Philippines primed with 2 or 3 doses of CoronaVac, with recombinant protein vaccine, SCB-2019. Methods: CoronaVac-immunized adults (18-72 years)...
5.
Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study
Buntinx E, Brochado L, Borja-Tabora C, Yu C, Alberto E, Montellano M, et al.
Vaccine . 2023 Feb; 41(11):1875-1884. PMID: 36781334
Background: We evaluated immunogenicity of SCB-2019, a subunit vaccine candidate containing a pre-fusion trimeric form of the SARS-CoV-2 spike (S)-protein adjuvanted with CpG-1018/alum. Methods: The phase 2/3, double-blind, randomized SPECTRA...
6.
Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021
B Gilbert P, Isbrucker R, Andrews N, Goldblatt D, Heath P, Izu A, et al.
Vaccine . 2022 Jul; 40(32):4283-4291. PMID: 35779963
Worldwide, childhood mortality has declined significantly, with improvements in hygiene and vaccinations against common childhood illnesses, yet newborn mortality remains high. Group B Streptococcus (GBS) disease significantly contributes to newborn...
7.
Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years
Chichili G, Smulders R, Santos V, Cywin B, Kovanda L, Van Sant C, et al.
Vaccine . 2022 Jun; 40(31):4190-4198. PMID: 35690500
Background: Pneumococcal diseases remain prevalent despite available polysaccharide and conjugate vaccines. This phase 1/2 study evaluated safety/tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine (ASP3772) based on high-affinity complexing...
8.
Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial
Smolenov I, Han H, Li P, Baccarini C, Verhoeven C, Rockhold F, et al.
Lancet Infect Dis . 2022 Apr; 22(7):990-1001. PMID: 35447085
Background: We previously reported the efficacy of the adjuvanted-protein COVID-19 vaccine candidate S-Trimer (SCB-2019) in adults who showed no evidence of previous exposure to SARS-CoV-2. In this study, we aimed...
9.
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial
Bravo L, Smolenov I, Han H, Li P, Hosain R, Rockhold F, et al.
Lancet . 2022 Jan; 399(10323):461-472. PMID: 35065705
Background: A range of safe and effective vaccines against SARS CoV 2 are needed to address the COVID 19 pandemic. We aimed to assess the safety and efficacy of the...
10.
Towards a population-based threshold of protection for COVID-19 vaccines
Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadska D, et al.
Vaccine . 2021 Dec; 40(2):306-315. PMID: 34933765
Correlates of protection for COVID-19 vaccines are urgently needed to license additional vaccines. We measured immune responses to four COVID-19 vaccines of proven efficacy using a single serological platform. IgG...